CVE:RVV Revive Therapeutics (RVV) Stock Price, News & Analysis C$0.08 +0.01 (+14.29%) As of 07/22/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Revive Therapeutics Stock (CVE:RVV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Revive Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.08▼C$0.0950-Day RangeC$0.08▼C$0.0852-Week RangeC$0.07▼C$0.25Volume212,852 shsAverage Volume93,085 shsMarket CapitalizationC$5.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRevive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.Read More… Receive RVV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RVV Stock News HeadlinesRevive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 13, 2025 | finanznachrichten.deRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comHow he turns Zzzzzzz’s into $$$$$’sMost traders don’t realize this… But the closing bell means jack $#!&. They hear the bell and they think “time to go”... But when Tim Sykes hears the bell?May 30, 2025 | Timothy Sykes (Ad)Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comRevive Therapeutics Ltd. (RVV.NE)April 18, 2025 | ca.finance.yahoo.comRevive Therapeutics Ltd.: Revive Therapeutics to Investigate Bucillamine's Potential in Cancer TreatmentApril 10, 2025 | finanznachrichten.deRevive Therapeutics to Investigate Bucillamine’s Potential in Cancer TreatmentApril 10, 2025 | financialpost.comRevive Therapeutics Announces Acquisition of Molecular Hydrogen ProgramApril 1, 2025 | markets.businessinsider.comSee More Headlines RVV Stock Analysis - Frequently Asked Questions How have RVV shares performed this year? Revive Therapeutics' stock was trading at C$0.08 at the beginning of 2025. Since then, RVV shares have increased by 0.0% and is now trading at C$0.08. View the best growth stocks for 2025 here. How do I buy shares of Revive Therapeutics? Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Revive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revive Therapeutics investors own include Aurora Cannabis (ACB), IntelGenx Technologies (IGXT), Vaxart (VXRT), Plug Power (PLUG), Sorrento Therapeutics (SRNE), Green Organic Dutchman (TGOD) and Zoom Video Communications (ZM). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:RVV CIKN/A Webwww.revivethera.com Phone+1-905-6055535FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.03 per share Price / Cash Flow3.18 Book ValueC$0.02 per share Price / Book4.21Miscellaneous Outstanding Shares72,411,000Free FloatN/AMarket CapC$5.79 million OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (CVE:RVV) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored"I'm risking my reputation on this"The Secret Behind 90% of Crypto’s Biggest Gains There are plenty solution-driven opportunities emerging rig...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revive Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Revive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.